Search Results for: ANTIBODY DRUG CONJUGATES ADC Development
Articles
GLOBAL DELIVERY MARKET - Advanced Drug Delivery Systems: mAb, RNAi, & Breaking the Blood-Brain Barrier November 19, 2014
Kevin James, Shalini Dewan, MS, Kim Lawson, and Usha Nagavarapu believe advances in understanding human biology and diseases are opening new and exciting possibilities in the biotechnology industry. R&D spending, along with increasing competition, patent expiries, and new and emerging technologies will continue to shape growth in this market for the foreseeable future.
Seattle Genetics & Genmab Enter New Antibody-Drug Conjugate Collaboration September 14, 2014
Seattle Genetics, Inc. and Genmab A/S recently announced the companies have entered into an additional antibody-drug conjugate (ADC) collaboration. Under...PEPTIDES & ANTIBODIES - Peptides in Antibody & Peptide Drug Conjugates July 7, 2014
Archana Gangakhedkar, MS, and Jyothi Thundimadathil, PhD, indicate peptide-based linkers are promising counterparts in ADCs, providing tumor-specific cleavable and stable circulating linkers, and a new emerging class of PDCs is proving to be useful toward a broad spectrum of indications when compared to ADCs.
PolyTherics & TUBE Pharma Form Development Collaboration October 21, 2013
PolyTherics Limited and TUBE Pharma GmbH recently announced they are collaborating to produce reagents to link novel cytotoxic drugs developed...Catalent Biologics Expands Into ADCs Through Exclusive License April 14, 2013
Catalent Pharma Solutions recently announced it has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag precision protein-chemical engineering...Mersana Therapeutics Strikes $270 Million Antibody-Drug Conjugate Deal March 7, 2012
Mersana Therapeutics, Inc. recently announced it has entered into a collaboration agreement with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates...Recipharm & Exela Announce Exclusive Strategic Alliance October 1, 2024
Recipharm and Exela Pharma Sciences recently announced their exclusive strategic alliance aimed at enhancing sterile manufacturing capabilities in the US....Araris Biotech AG Expands IP Portfolio With Acquisition of Innate Pharma’s Portfolio September 24, 2024
Araris Biotech AG recently announced it has entered into an agreement with Innate Pharma. Under the agreement, Innate will assign...Enable Injections & Serina Therapeutics Announce Agreement to Develop SER-252 in Combination With enFuse for Advanced Parkinson’s Disease May 15, 2024
Enable Injections, Inc. and Serina Therapeutics recently announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse...Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024 May 14, 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of….
Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology February 21, 2024
Vaccinex, Inc. recently announced it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform...PathAI Announces Exclusive Collaboration With Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics February 14, 2024
PathAI, Inc. recently announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion...Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies February 8, 2024
Abzena recently announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly….
EXECUTIVE INTERVIEW - Samsung Biologics: Exploring The Evolving Biopharma Landscape January 26, 2024
Kevin Sharp, Senior VP & Head of Sales for Samsung Biologics, discusses the evolving biopharma space, exploring current challenges, and the demand for sustainable solutions.
Nectin Therapeutics Adds Combination Therapy Arm & Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent December 19, 2023
Nectin Therapeutics Ltd. recently announced it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy...AbbVie to Acquire ImmunoGen, Including its Flagship Cancer Therapy, Expanding Solid Tumor Portfolio December 1, 2023
AbbVie Inc. and ImmunoGen, Inc. recently announced a definitive agreement under which AbbVie will acquire ImmunoGen and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class….
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services September 26, 2023
MilliporeSigma is the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and….
Pyxis Oncology to Acquire Apexigen May 24, 2023
Pyxis Oncology, Inc. and Apexigen, Inc. recently announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of….
Absci Enters Multi-Program Collaboration With Emerging Biotech Partner July 7, 2022
Absci Corporation recently announced it has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by….
Sterling Pharma Solutions Expands Capabilities & Laboratory Capacity April 5, 2022
Sterling Pharma Solution recently announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated...
